echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Anti-cancer drugs combined with artemisinin, two-pronged attack on drug-resistant malaria parasites!

    Anti-cancer drugs combined with artemisinin, two-pronged attack on drug-resistant malaria parasites!

    • Last Update: 2021-02-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Scientists have found a way to use chemotherapy drugs to dramatically enhance the efficacy of the world's most effective antimalarial drugs, according to a new study published in Nature Communications. Scientists from the University of Melbourne and Japanese drug company Takeda have found that the antimalarial drug artemisinin is effective by attacking the deadly malaria parasite with a dual effect. The drug damages proteins on the surface of the malaria parasite and clogs the plasmodium's waste disposal system, the protease.
    Leann Tilley, a malaria researcher at the University of Melbourne, said: "The double-killing effect means that the combination of artemisinin and another cancer chemotherapy drug targeting proteases to enhance artemisinin activity can effectively restore artemisinin's ability to fight artemisinin-resistant pathogens.
    about 450,000 people die each year from malaria worldwide, and pathogens in South-East Asia have developed artemisinin resistance, which could spread to Greater Africa in the near future.
    ", the parasite's protease is like a shredder that can tear up damaged or useless proteins. Tilley said. Treating malaria parasites with artemisinin produces many damaged proteins. Artemisinin and protease inhibitors can join forces to block this path. "Inhibiting proteases can cause damaged proteins to accumulate, which is one of the hallmarks of the kiss of death. But when these damaged proteins build up, they can put pressure on the parasites and eventually kill them.
    Tilley and her team worked with Takeda and the Swiss Nonprofit Research Foundation's Malaria Drug Project to try to find inhibitors that specificly inhibit the plasmodium plasmodium protease in order to get into clinical trials as quickly as possible. "We are now conducting pharmaceutical chemistry research to try to develop inhibitors similar to human protease inhibitors to specificly inhibit the proteases of pathogens." Professor Tilley said. "We want a drug that can be used orally and can be present in the blood for a long time, and if we can find the right drug, we will start clinical trials in humans as soon as possible." (Bio Valley)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.